With the advent of transgenic technology, novel animal models are being developed to facilitate prostate cancer research. The ability to perform genetic perturbation studies in a temporally and spatially restricted manner has established a new paradigm for investigations of the molecular mechanisms involved in the initiation, progression and metastogenesis of prostate cancer. Using the transgenic adenocarcinoma of the mouse prostate (TRAMP) model we have begun to identify speci®c molecular events related to the emergence of the androgen-insensitive phenotype. In addition, a number of new models have recently been generated to characterize how the deregulation of stromal to epithelial interactions mediated by polypeptide growth factor signaling could facilitate transformation of the prostate. It is anticipated that these models and their successors will ultimately provide new molecular pathway-based strategies for the prevention, detection and treatment of prostate cancer. Prostate Cancer and Prostatic Diseases (2000) 3, 224±228.
Introduction
The chances of surviving prostate cancer increase with early diagnosis and early therapy. In order to facilitate prevention for those at risk of developing prostate cancer, and to better develop diagnostics and therapeutics for patients it is imperative that we understand the molecular mechanisms contributing to the initiation and progression of the disease. Hence there is an immediate need for adequate supply of tissue samples representing early, advanced and metastatic prostate cancers. Although numerous tissue banks and repositories are being established, it is still rather dif®cult to obtain adequate clinical research material representing the entire spectrum of clinical disease. Fortunately immortalized cell lines continue to be derived from clinical tumor specimens; however these reagents mostly represent advanced disease and, a priori, preclude investigation of the earliest events related to initiation and progression. The paucity of clinical material has thus hastened the identi®cation of alternative sources of primary spontaneous prostate cancer. As the prostate is a complex organ made up, in part, of epithelial, mesenchymal, endothelial, lymphatic, neuroendocrine and other intricately related compartments, the clear imperative has been to move expeditiously toward autochthonous mammalian systems in order to comprehensively study prostate cancer in vivo. To this end my laboratory has employed genetic engineering technology to establish novel inbred transgenic mouse models. Since these mice develop spontaneous autochthonous disease, they can be exploited to study how speci®c genetic events cause or correlate with the initiation, progression and metastasis of prostate cancer. Furthermore inbred transgenic mice have intact immune and endocrine systems and therefore can be used to characterize how tumors escape immune surveillance as well as to understand the molecular basis of androgen-insensitive prostate cancer. For the purpose of this discussion I will focus primarily on the strategy used in my laboratory to develop these animal models as well as on our studies on steroid and polypeptide hormone signals and how functional deregulation of these signaling pathways in vivo may contribute to prostate cancer.
The TRAMP model
Together with our collaborators we have developed a system based on the rat probasin promoter to target heterologous gene expression speci®cally to the mouse prostate in a developmentally-and hormonally-regulated fashion. 1 As a result of these studies it was determined that a an expression cassette carrying 426 base pairs (bp) of the rat probasin (PB) gene promoter and 28 bp of 5 0 untranslated region (5 0 UT) was suf®cient to target the expression of the bacterial chloramphenicol acetyl transferase (CAT) gene speci®cally to the prostate in transgenic mice. 1 The transgene was found to be developmentally regulated and hormonally regulated by androgens. Subsequently, we assembled a recombinant transgene carrying the minimal probasin promoter fused to the SV40 early genes (T and t antigens; Tag). The rationale for building this particular construct was based upon the observation that Rb and p53 were often mutated or lost in clinical prostate cancer. 2, 3 Since Tag can effectively bind and abrogate the function of these very same tumor suppressor gene products, 4 ± 6 the overall objective of this study was, in fact, to test the hypothesis that inactivation of p53 and Rb would lead to prostate cancer. In short, this was the most expedient method to achieve the strategic objective and therefore the PB-Tag construct was used to generate transgenic mice in the C57BL/6 inbred strain. Subsequently, line 8247 was used to establish the transgenic adenocarcinoma mouse prostate (TRAMP) model. 7 We have since determined that the phenotype of the TRAMP tumors is a function of the strain and that strain speci®c responses will in¯uence the rate of tumor growth and frequency of distant site metastasis. 8 For this reason we currently cross the C57BL/6 TRAMP mice to non-transgenic FVB/n mice to obtain [C57BL/6 6 FVB] F1 TRAMP males for our studies. For the sake of simplicity I will hereafter refer only to the [C57BL/6 6 FVB] F1 TRAMP males.
In the TRAMP mice, expression of the PB-Tag transgene is spatially restricted to the dorsolateral lobes of the prostate and the temporal pattern of transgene expression correlates with sexual maturity and is hormonally regulated by androgens. The TRAMP mice reproducibly develop progressive forms of prostate disease, from prostatic intraepithelial hyperplasia (PIN) to invasive adenocarcinoma with distant site metastasis to the lymph node, lung, and bone. 9, 10 By the time TRAMP males are 24 ± 30 weeks of age, 100% will display primary tumors and metastatic disease. Following castration at 12 weeks of age approximately 80% of the TRAMP males will develop androgen-independent disease. 11 Taken together, these observations illustrate how the initiation, progression and metastasis of prostate cancer in the TRAMP model closely parallel that observed in human prostate cancer. 8 Therefore, this model provides a valuable resource with which to study the molecular basis of prostate cancer.
The androgen signalling axis
While the role of the androgen signalling axis in the development, growth and homeostasis of the prostate gland is generally appreciated, we in fact know very little about the molecular mechanisms that directly or indirectly execute these androgenic signals. Nevertheless, androgen ablation is generally the most effective therapy for recurrent, locally advanced and metastatic prostate cancer. However, the consequence of androgen ablation with respect to overall survival is still questionable, as evident from the common emergence of androgen independent disease. The current imperative is to elucidate the molecular biology of this process and to design more effective clinical intervention strategies. The objective here will be to discuss a working hypothesis regarding the role of the androgen receptor (AR) in prostate cancer.
The mechanism of androgen action in the prostate is complex. In the homeostatic state the adult prostate actually displays a remarkably low proliferative index despite high levels of circulating androgen. This is consistent with the hypothesis that the androgen signalling axis promotes the post-mitotic terminal and functional differentiation of the prostate. This observation is also clearly in contrast to the convention supporting androgen as a pro-proliferative signal even though androgen ablation will initially lead to regression of the epithelial compartment. This latter observation is more likely the consequence of abrogation of androgen supported growth and survival factors, as will be discussed later. In some instances, androgen ablation may actually facilitate progression of prostate cancer once the cells of the prostate have undergone some degree of transformation. To explain the apparent paradox that androgen ablation can promote both regression and proliferation, it is essential to consider that elimination of the androgen ligand need not necessarily imply abrogation of the ability of the AR to issue a transcriptional signal in a ligandindependent fashion.
It is proposed that speci®c changes to the level of expression or structure of the AR or the cognate signaling cofactors can play a very important and central role in the progression and metastasis of prostate cancer. There is strong evidence to support this hypothesis. For example mutations in the androgen receptor have been associated with the progression of human prostate cancer to androgen independence. 12 Furthermore, deregulated androgen receptor function, as a consequence of mutation, has been associated with altered response to hormone ligands such as estradiol, 13¯u tamide, 14 progesterone, dehydroepiandrosterone, androstenedione 15 and glucocorticoids. 16, 17 Based on these studies it appears that mutated forms of AR may provide a selective growth advantage and implicate these variants in tumor genesis, progression and metastasis.
There is considerable controversy in the literature concerning the frequency and incidence of mutations in the AR in prostate cancer. Using single-strand conformational polymorphism (SSCP) analysis some groups have demonstrated a low incidence of AR mutations prior to therapy and in relapsed disease 18 or in metastatic disease using immunohistochemistry. 19 However, there is now overwhelming evidence that spontaneous somatic mutations do occur in the AR that can be detected in primary, advanced and metastatic forms of prostate cancer as well as in cell lines derived from advanced disease. 12,13,15,19 ± 23 In fact, over 200 human androgen receptor mutations associated with androgen-insensitive syndromes and prostate cancer have been reported. 20 Although the majority of the reported mutations in the androgen receptor are silent (171/212; 80.7%), at least 20 (9.4%) result in aberrant transcripts and 21 (10%) result in structural defects (complete or partial gene deletions or small deletions and insertions). Analysis of the incidence and nature of these mutations has identi®ed at least twò hot spots' for mutation in exons 5 and 7 that account for 37% and 18% of the mutations, respectively. The respective mutation densities for these regions are 68% and 39%, respectively. On the basis of this data, it is clear that androgen receptor is a target for somatic mutation and it is therefore tempting to speculate on the causal relationship between mutations in AR and prostate cancer.
It has been dif®cult to undertake a comprehensive analysis of the incidence and nature of spontaneous mutations in androgen receptors in prostate cancer because prostate cancer is a heterogeneous disease of a genetically heterogeneous human population. To study the androgen signaling axis we are using the TRAMP model and have now determined that somatic mutations in the AR can be identi®ed and isolated in prostate cancer from intact and castrated mice (G Han, manuscript in preparation). The next immediate objective will be to determine the incidence, frequency and nature of somatic AR mutations during development of prostate cancer in the TRAMP model and to determine if selection for speci®c AR mutations occurs as a consequence of physical or chemical castration. To this end, tissue samples are being isolated at various time points during prostate cancer progression from intact and castrate cohorts of TRAMP mice, and SSCP analysis will be performed to identify putative AR mutations. The nature of the AR mutations will be con®rmed by cDNA cloning and sequence analysis and full-length mutated AR cDNA will be isolated and ligated into eukaryotic expression plasmids to facilitate functional characterization.
Peptide growth factors
Growth and differentiation of the prostate is an androgen dependent mechanism mediated through stromal-epithelial interactions. 24 ± 29 However, the molecular mechanism whereby androgens in¯uence the mesenchyme to induce and direct ductal morphogenesis, cytodifferentiation and the formation of mature prostatic glandular acini remains to be characterized. Keratinocyte growth factor (KGF) is one member of the heparin binding ®broblast growth factor (FGF) family. This was the ®rst polypeptide growth factor to be implicated as an andromedin, that is, a factor synthesized in the stromal compartment that indirectly mediates androgen action on prostate epithelial cells to in¯uence their differentiation and function. 26, 27, 30, 31 Studies by Nishi et al 32 have demonstrated that levels of steady state mRNA for FGF-2, KGF and FGFR1 increased 2 ± 4-fold in the dorsolateral rat prostate following castration. Hence subtle changes following castration (ie elaboration of the FGFR1 gene not normally expressed in differentiated epithelium 33 ) may facilitate disease progression to a form that is independent of androgens and stroma. Furthermore, over-expression of FGF-8, another member of the FGF family of ligands, has also been reported in human prostate cancer and the level of FGF-8 expression was found to be related to advanced grade. 34 Given the implication of KGF in normal prostate development and cancer, the ability to direct KGF expression directly to the epithelial cells of the developing prostate would help re®ne the role of KGF in stromal ± epithelial interactions and test the hypothesis that converting the mode of action of KGF from paracrine to autocrine will lead to hyperplasia and possible carcinoma of the prostate. Similar strategies have been used to de®ne the role of KGF in the dermal ± epidermal regulation of keratinocyte growth and differentiation. 35 We have now established three independent lines of mice carrying a transgene comprised of the minimal probasin promoter driving expression of KGF (PB-KGF; B Foster, manuscript in preparation). All three lines express the transgene in the dorsolateral prostate. Histological analysis indicated that the epithelial cells of the dorsolateral prostate in three of the PKS lines were hyperplastic. The lumens were often ®lled with epithelial cells, as well as some secretion. There were also areas of stromal thickening and distortion of the smooth muscle was associated with the prostatic ducts. These observations generally support our hypothesis that epithelial hyperplasia is a consequence of deregulated KGF signalling.
Since KGF is normally expressed by the stromal compartment and signals via an epithelial receptor, studies using dominant negative mutant FGF-receptors are also underway to determine the consequence of FGF signal ablation. We have now established independent lines of mice carrying a transgene comprised of the minimal probasin promoter driving expression of a dominant negative FGFR2IIIb construct (PB-KDNR; B Foster, manuscript in preparation) designed to interrupt KGF signals speci®cally in the epithelium of the prostate. Preliminary dissection and gross observation of the reproductive tracts of the remaining three KDNR lines indicated that all lobes of the prostate were intact. However, in at least one of the lines the dorsolateral prostate was approximately 50% of normal size. Histological analysis demonstrated that the epithelium of the dorsolateral prostate was very disorganized, in contrast to the PB-KGF mice. Therefore, expression of the dominant negative KGF receptor appeared to disrupt epithelial ± mesenchymal interactions, resulting in poorly organized epithelium and stroma.
From these few examples it is evident that by manipulating the expression of growth factor genes and their cognate receptors, transgenic mice have successfully been used to determine how such genetic perturbations in¯u-ence the growth properties of a variety of cell types. Clearly, the ability to target heterologous gene expression to the prostate of transgenic mice will facilitate characterization of the roles of these and other peptide hormones in stromal ± epithelial interactions during prostate growth, differentiation and tumorigenesis.
Androgens and growth factors working together
It has previously been demonstrated that members of the steroid hormone receptor superfamily that includes the estrogen receptor (ER) and progesterone receptor (PR), can facilitate gene expression in response to peptide growth factors insulin-like growth factor-1 (IGF-1), epidermal growth factor (EGF) 36 ± 39 and heregulin. 40 Furthermore, ER dependent transcription can be activated by cAMP 36 and protein kinase activators 38 while PR-dependent transcription can be activated by dopamine. 39 It has also been demonstrated that IGF-1, EGF and KGF directly activate AR in the absence of androgen ligand 41 and that IGF-1 is more potent than KGF or EGF. This latter observation was not surprising given that IGF-1 has been shown to ef®ciently stimulate proliferation of prostate cell epithelial (PC-E) cells in culture. 42 In all, these ®ndings provide evidence that activation of the hormone signalling pathway can occur as a consequence of ligand independent activation of steroid hormone receptors. This also suggests that the degree of crosstalk between growth factor and hormone signalling pathways may vary with the nature of the mutation in the AR. It should be interesting to study these interactions in an autochthonous model system
Concluding remarks
Tissue-speci®c genetic perturbation technology has facilitated the generation of a new class of models for prostate cancer research. These transgenic models are already demonstrating their utility in pre-clinical studies to evaluate novel chemotherapeutic 43 and immunotherapeutic 44, 45 , strategies in both the basic and applied research communities. With the advent of so called`gene-chips' and other array-based tools for genome wide screening and analysis, it is likely that these transgenic models and their successors will also demonstrate great utility for the identi®cation of novel sets of prostate cancer associated genes. Furthermore, these models will be useful to identify novel diagnostic markers and to assess molecular responses to speci®c therapeutic interventions.
